13D Filings
BioLife Solutions, Inc.
BLFS
Amendment
Ownership

12.40%

Total Shares

5,957,165

Issuer CIK

834365

CUSIP

09062W204

Event Date

Oct 14, 2025

Accepted

Oct 17, 2025, 08:04 PM

Reporting Persons (4)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Casdin Capital, LLC
Investment Adviser
12.40%5,957,16505,957,165
Casdin Partners Master Fund, L.P.
Partnership
12.40%5,957,16505,957,165
Casdin Partners GP, LLC
Other
12.40%5,957,16505,957,165
Eli Casdin
Individual
12.40%5,957,16505,957,165
Disclosure Items (7)

Security Title

Common Stock, par value $0.001 per share

Issuer Name

BioLife Solutions, Inc.

Issuer Address

3303 Monte Villa Parkway,, Bothell, WA, 98021

Filing Persons

This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company ("Casdin"), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), Casdin Partners GP, LLC, a Delaware limited liability company (the "GP") and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").

Business Address

The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.

Principal Occupation

Eli Casdin is the managing member of Casdin and the GP. The principal business of Casdin is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Casdin is the investment manager to the Fund and the GP is the general partner of the Fund. The principal business of the Fund is purchasing, holding and selling securities for investment purposes.

Convictions

During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group.

Citizenship

This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company ("Casdin"), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), Casdin Partners GP, LLC, a Delaware limited liability company (the "GP") and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").

The funds for the purchase of the Shares by the Fund came from the working capital of the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.

The Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present Board of Directors or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be listed from a national securities exchange or to ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or (g) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934. The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own. The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.

As of the date hereof, Casdin, the Fund, the GP and Eli Casdin may be deemed to be the beneficial owners of 5,957,165 Shares, constituting 12.4% of the Shares based upon 47,905,265* Shares outstanding. Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 5,957,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 5,957,165 Shares. The Fund has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 5,957,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 5,957,165 Shares. The GP has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 5,957,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 5,957,165 Shares. Eli Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 5,957,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 5,957,165 Shares. The transactions by the Reporting Persons in the Shares are set forth in Exhibit B. *This outstanding Shares figure reflects the number of outstanding Shares as of July 31, 2025.

Not Applicable.

Exhibit A: Joint Filing Agreement Exhibit B: Schedule of Transactions in Shares

BioLife Solutions, Inc. — Schedule 13D | 13D Filings